Drug Trial Radar · NCT07209332
Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
175
Planned (sponsor's estimate)
Start
Dec 28, 2025
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Wave Life Sciences USA, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 open-label extension (OLE) study to evaluate the long-term safety, tolerability, efficacy, pharmacokinetics, and the pharmacodynamics (PD) through potential exploratory biomarker(s) of intravenous (IV) WVE-N531 in patients with DMD who participated in another study of WVE-N531. All patients will have rolled over from a previous study of WVE-N531.
Conditions
- Duchenne Muscular Dystrophy
Interventions
WVE-N531Drug
WVE-N531 is an antisense oligonucleotide (ASO)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment related adverse events as assessed by the following parameters:Time frame: Time Frame: Week 0 through Week 96
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Istiklal Hospital/ Clinical Research Unit
Amman, Jordan
The Specialty Hospital (TSH)/ Advanced Clinical Center
Amman, Jordan
Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust
Headington, Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.